Want to join the conversation?
Global pharmaceutical giant $ABBV today got the approval of VIEKIRAX from Japanese Ministry of Health, Labour and Welfare for the treatment of adult patients with HCV-1 infection, including those with compensated liver cirrhosis. With this approval, $ABBV is going to address the unmet need of approx. 2MM HCV patients in Japan.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!